Macrophages-derived exosomal lncRNA LIFR-AS1 promotes osteosarcoma cell progression via miR-29a/NFIA axis

被引:51
|
作者
Zhang, Hongliang [1 ,2 ]
Yu, Yiyang [1 ,2 ]
Wang, Jun [1 ,2 ]
Han, Yu [1 ,2 ]
Ren, Tingting [1 ,2 ]
Huang, Yi [1 ,2 ]
Chen, Chenglong [1 ,2 ]
Huang, Qingshan [1 ,2 ]
Wang, Wei [1 ,2 ]
Niu, Jianfang [1 ,2 ]
Lou, Jingbing [1 ,2 ]
Guo, Wei [1 ,2 ]
机构
[1] Peking Univ Peoples Hosp, Musculoskeletal Tumor Ctr, 11 Xizhimen South St, Beijing 100044, Peoples R China
[2] Beijing Key Lab Musculoskeletal Tumor, Beijing, Peoples R China
基金
中国国家自然科学基金;
关键词
Bone tumor; Tumor-associated macrophages; Exosomal lncRNA; LIFR-AS1; Exosome; LONG NONCODING RNAS; CANCER; CHEMOTHERAPY; METASTASIS; EXTREMITY; INVASION;
D O I
10.1186/s12935-021-01893-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundOsteosarcoma (OS) is the most common primary malignant bone tumor in young people. Tumor-associated macrophages (TAMs) have been reported to play an important role in the development of osteosarcoma. However, the detailed molecular mechanisms remain largely unknown and need to be elucidated. Recently, exosomes have been reported as the crucial mediator between tumor cells and the tumor microenvironment. And a lot of lncRNAs have been reported to act as either oncogenes or tumor suppressors in osteosarcoma. In this research, we aim to explore the role of macrophages-derived exosomal lncRNA in osteosarcoma development and further elucidated the potential molecular mechanisms involved.MethodsTAMs were differentiated from human mononuclear cells THP-1, and a high-throughput microarray assay was used to analyze the dysregulated lncRNAs and miRNAs in osteosarcoma cells co-cultured with macrophages-derived exosomes. Western blot, qRT-PCR assays, and Dual-luciferase reporter assay were used to verify the interaction among LIFR-AS1, miR-29a, and NFIA. Cck-8, EdU, colony formation assay, wound-healing, and transwell assay were performed to explore the characterize the proliferation and metastasis ability of OS cells. And qPCR, Western blots, immunohistochemistry, and cell immunofluorescence were used to detect the expression of relative genes or proteins.ResultsIn this study, we found that THP-1-induced macrophage-derived exosomes could facilitate osteosarcoma cell progression both in vitro and in vivo. Then, the results of the high-throughput microarray assay showed that LIFR-AS1 was highly expressed and miR-29a was lowly expressed. Furthermore, LIFR-AS1 was identified as a miR-29a sponge, and NFIA was validated as a direct target of miR-29a. Functional assays demonstrated that knockdown of exosomal LIFR-AS1 could attenuate the promotion effects of macrophages-derived exosomes on osteosarcoma cell progression and miR-29a inhibition could reserve the effect of LIFR-AS1-knockdown exosomes. Correspondingly, NFIA-knockdown could partially reverse the tumor inhibition effect of miR-29a on osteosarcoma cells.ConclusionsTaken together, macrophages-derived exosomal lncRNA LIFR-AS1 can promote osteosarcoma cell proliferation, invasion, and restrain cell apoptosis via miR-29a/NFIA axis, which can act as a potential novel therapeutic target for osteosarcoma therapy.
引用
收藏
页数:14
相关论文
共 50 条
  • [1] Macrophages-derived exosomal lncRNA LIFR-AS1 promotes osteosarcoma cell progression via miR-29a/NFIA axis
    Hongliang Zhang
    Yiyang Yu
    Jun Wang
    Yu Han
    Tingting Ren
    Yi Huang
    Chenglong Chen
    Qingshan Huang
    Wei Wang
    Jianfang Niu
    Jingbing Lou
    Wei Guo
    Cancer Cell International, 21
  • [2] LncRNA LIFR-AS1 promotes proliferation and invasion of gastric cancer cell via miR-29a-3p/COL1A2 axis
    Haiyan Pan
    Yuanlin Ding
    Yugang Jiang
    Xingjie Wang
    Jiawei Rao
    Xingshan Zhang
    Haibing Yu
    Qinghua Hou
    Tao Li
    Cancer Cell International, 21
  • [3] LncRNA LIFR-AS1 promotes proliferation and invasion of gastric cancer cell via miR-29a-3p/COL1A2 axis
    Pan, Haiyan
    Ding, Yuanlin
    Jiang, Yugang
    Wang, Xingjie
    Rao, Jiawei
    Zhang, Xingshan
    Yu, Haibing
    Hou, Qinghua
    Li, Tao
    CANCER CELL INTERNATIONAL, 2021, 21 (01)
  • [4] Exosomal lncRNA CHL1-AS1 Derived from Peritoneal Macrophages Promotes the Progression of Endometriosis via the miR-610/MDM2 Axis
    Liu, Ting
    Liu, Mei
    Zheng, Caihua
    Zhang, Daoyan
    Li, Mingbao
    Zhang, Lu
    INTERNATIONAL JOURNAL OF NANOMEDICINE, 2021, 16 : 5451 - 5464
  • [5] M2 macrophages-derived exosomal miR-3917 promotes the progression of lung cancer via targeting GRK6
    Song, Sinuo
    Zhao, Yunping
    Wang, Xiaoxing
    Tong, Xinghe
    Chen, Xiaobo
    Xiong, Qiuxia
    BIOLOGICAL CHEMISTRY, 2023, 404 (01) : 41 - 57
  • [6] Functional role of a long non-coding RNA LIFR-AS1/miR-29a/TNFAIP3 axis in colorectal cancer resistance to pohotodynamic therapy
    Liu, Kuijie
    Yao, Hongliang
    Wen, Yu
    Zhao, Hua
    Zhou, Nanjiang
    Lei, Sanlin
    Xiong, Li
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2018, 1864 (09): : 2871 - 2880
  • [7] LncRNA PCAT-1 promotes the progression of osteosarcoma via miR-508-3p/ZEB1 axis
    Chang, L.
    Jia, D-L
    Cao, C-S
    Wei, H.
    Li, Z-Q
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2021, 25 (06) : 2517 - 2527
  • [8] Osteosarcoma Cell-Derived Exosomal miR-1307 Promotes Tumorgenesis via Targeting AGAP1
    Han, Fei
    Pu, Peidong
    Wang, Chao
    Ding, Xiao
    Zhu, Zhoujun
    Xiang, Wei
    Wang, Weishan
    BIOMED RESEARCH INTERNATIONAL, 2021, 2021
  • [9] lncRNA LIFR-AS1 suppresses invasion and metastasis of non-small cell lung cancer via the miR-942-5p/ZNF471 axis
    Qun Wang
    Jing Wu
    Hui Huang
    Yan Jiang
    Ying Huang
    Hongyan Fang
    Gang Zheng
    Xiaochun Zhou
    Yujuan Wu
    Changjiang Lei
    Desheng Hu
    Cancer Cell International, 20
  • [10] lncRNA LIFR-AS1 suppresses invasion and metastasis of non-small cell lung cancer via the miR-942-5p/ZNF471 axis
    Wang, Qun
    Wu, Jing
    Huang, Hui
    Jiang, Yan
    Huang, Ying
    Fang, Hongyan
    Zheng, Gang
    Zhou, Xiaochun
    Wu, Yujuan
    Lei, Changjiang
    Hu, Desheng
    CANCER CELL INTERNATIONAL, 2020, 20 (01)